Cargando…

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma

Detalles Bibliográficos
Autor principal:	Orlowski, Robert Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2018
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398024/ https://www.ncbi.nlm.nih.gov/pubmed/29694283 http://dx.doi.org/10.18553/jmcp.2018.24.5.487

Ejemplares similares

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2018)

Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
por: Stork, Martin, et al.
Publicado: (2023)

Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practice
por: Hulin, Cyrille, et al.
Publicado: (2018)

Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
por: Shah, Jatin J, et al.
Publicado: (2009)

Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs
por: Gooding, Sarah, et al.
Publicado: (2015)

Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
por: Huang, Shang-Yi, et al.
Publicado: (2019)

Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A “real world” experience
por: Fucci, Ludovica, et al.
Publicado: (2022)

Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary
por: Lovas, Szilvia, et al.
Publicado: (2022)

Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe
por: Terpos, Evangelos, et al.
Publicado: (2022)

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
por: Chan, Kelvin, et al.
Publicado: (2020)

The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma
por: MacEwan, Joanna P, et al.
Publicado: (2021)

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
por: Chim, C S, et al.
Publicado: (2018)

Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
por: Krishnan, Amrita, et al.
Publicado: (2023)

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
por: Jagannath, Sundar, et al.
Publicado: (2021)

Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study
por: Macro, M., et al.
Publicado: (2023)

The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies
por: Szabo, Agoston Gyula, et al.
Publicado: (2023)

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
por: Chim, C. S., et al.
Publicado: (2019)

Real‐world data on safety and efficacy of venetoclax‐based regimens in relapsed/refractory t(11;14) multiple myeloma
por: Basali, Diana, et al.
Publicado: (2020)

Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study
por: Shragai, Tamir, et al.
Publicado: (2022)

PB2114: BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD OBSERVATIONAL STUDY UPDATE
por: Hultcrantz, Malin, et al.
Publicado: (2023)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Treatment of relapsed and refractory multiple myeloma
por: Lee, Ji Hyun, et al.
Publicado: (2020)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

PB2113: TREATMENT REFRACTORINESS AND RESPONSE RATES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA
por: Majd, Zahra, et al.
Publicado: (2023)

A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2021)

Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World “POWERFUL” Study
por: Terpos, Evangelos, et al.
Publicado: (2021)

PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Krishnan, A., et al.
Publicado: (2022)

P899: REAL-WORLD ASSESSMENT OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE OPTUM DATABASE
por: Dhakal, B., et al.
Publicado: (2022)

Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France
por: Lin, Huamao Mark, et al.
Publicado: (2019)

Evaluating Oncology Value-Based Frameworks in the U.S. Marketplace and Challenges in Real-World Application: A Multiple Myeloma Test Case
por: Djatche, Laurence M., et al.
Publicado: (2018)

Bendamustine in patients with relapsed or refractory multiple myeloma
por: Michael, M, et al.
Publicado: (2010)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

The role of carfilzomib in relapsed/refractory multiple myeloma
por: Yee, Andrew J.
Publicado: (2021)

A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2019)

P12: TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: RETROSPECTIVE CHART REVIEW OF REAL-WORLD OUTCOMES FOR STANDARD OF CARE
por: Vekemans, M-C, et al.
Publicado: (2022)

Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma—Experience From a Tertiary Care Cancer Center
por: Bondili, Suresh Kumar, et al.
Publicado: (2021)

P40 REAL-WORLD TREATMENT PATTERNS OF PATIENTS INITIATING THIRD-LINE THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA IN EUROPE
por: Lehne, M., et al.
Publicado: (2023)

Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma
por: Lecat, Catherine S. Y., et al.
Publicado: (2021)

Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
por: Baljevic, Muhamed, et al.
Publicado: (2017)

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
por: Iacoboni, Gloria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7jfk2mrpk99dtvfq3od55fp43e